WuXi Biologics Secures Brazil GMP Certification for Cancer Immunotherapy Manufacturing
Event summary
- WuXi Biologics' Wuxi facilities (MFG2, DP1, DPPC) received GMP certification from Brazil's ANVISA on June 30, 2026.
- The certification enables end-to-end commercial manufacturing of an anti-PD-L1 monoclonal antibody for cancer immunotherapy.
- ANVISA inspection yielded zero findings, validating WuXi Biologics' quality management and GMP execution.
- WuXi Biologics operates 15 GMP-certified facilities globally as of 2026.
The big picture
WuXi Biologics' ANVISA certification strengthens its position as a global CRDMO, enabling it to support clients' commercialization strategies in Latin America. The company's robust quality management system and end-to-end manufacturing capabilities are critical as biologic therapies gain traction worldwide. With 982 integrated client projects as of April 30, 2026, WuXi Biologics is well-positioned to capitalize on the growing demand for innovative cancer immunotherapies.
What we're watching
- Latin American Market Entry
- The pace at which WuXi Biologics can leverage this certification to expand its client base in Latin America.
- Regulatory Compliance
- Whether WuXi Biologics can maintain its 100% pass rate for FDA Pre-License Inspections amid increasing global regulatory scrutiny.
- Operational Scalability
- How the integration of digital capabilities will impact the efficiency and scalability of WuXi Biologics' manufacturing operations.
Related topics